Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ian F. Dunn is active.

Publication


Featured researches published by Ian F. Dunn.


Nature | 2009

Systematic RNA interference reveals that oncogenic KRAS -driven cancers require TBK1

David A. Barbie; Pablo Tamayo; Jesse S. Boehm; So Young Kim; Susan E. Moody; Ian F. Dunn; Anna C. Schinzel; Peter Sandy; Etienne Meylan; Claudia Scholl; Stefan Fröhling; Edmond M. Chan; Martin L. Sos; Kathrin Michel; Craig H. Mermel; Serena J. Silver; Barbara A. Weir; Jan H. Reiling; Qing Sheng; Piyush B. Gupta; Raymond C. Wadlow; Hanh Le; Ben S. Wittner; Sridhar Ramaswamy; David M. Livingston; David M. Sabatini; Matthew Meyerson; Roman K. Thomas; Eric S. Lander; Jill P. Mesirov

The proto-oncogene KRAS is mutated in a wide array of human cancers, most of which are aggressive and respond poorly to standard therapies. Although the identification of specific oncogenes has led to the development of clinically effective, molecularly targeted therapies in some cases, KRAS has remained refractory to this approach. A complementary strategy for targeting KRAS is to identify gene products that, when inhibited, result in cell death only in the presence of an oncogenic allele. Here we have used systematic RNA interference to detect synthetic lethal partners of oncogenic KRAS and found that the non-canonical IκB kinase TBK1 was selectively essential in cells that contain mutant KRAS. Suppression of TBK1 induced apoptosis specifically in human cancer cell lines that depend on oncogenic KRAS expression. In these cells, TBK1 activated NF-κB anti-apoptotic signals involving c-Rel and BCL-XL (also known as BCL2L1) that were essential for survival, providing mechanistic insights into this synthetic lethal interaction. These observations indicate that TBK1 and NF-κB signalling are essential in KRAS mutant tumours, and establish a general approach for the rational identification of co-dependent pathways in cancer.


Cell | 2007

Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene

Jesse S. Boehm; Jean Zhao; Jun Yao; So Young Kim; Ron Firestein; Ian F. Dunn; Sarah K. Sjostrom; Levi A. Garraway; Stanislawa Weremowicz; Andrea L. Richardson; Heidi Greulich; Carly J. Stewart; Laura Mulvey; Rhine R. Shen; Lauren Ambrogio; Tomoko Hirozane-Kishikawa; David E. Hill; Marc Vidal; Matthew Meyerson; Jennifer K. Grenier; Greg Hinkle; David E. Root; Thomas M. Roberts; Eric S. Lander; Kornelia Polyak; William C. Hahn

The karyotypic chaos exhibited by human epithelial cancers complicates efforts to identify mutations critical for malignant transformation. Here we integrate complementary genomic approaches to identify human oncogenes. We show that activation of the ERK and phosphatidylinositol 3-kinase (PI3K) signaling pathways cooperate to transform human cells. Using a library of activated kinases, we identify several kinases that replace PI3K signaling and render cells tumorigenic. Whole genome structural analyses reveal that one of these kinases, IKBKE (IKKepsilon), is amplified and overexpressed in breast cancer cell lines and patient-derived tumors. Suppression of IKKepsilon expression in breast cancer cell lines that harbor IKBKE amplifications induces cell death. IKKepsilon activates the nuclear factor-kappaB (NF-kappaB) pathway in both cell lines and breast cancers. These observations suggest a mechanism for NF-kappaB activation in breast cancer, implicate the NF-kappaB pathway as a downstream mediator of PI3K, and provide a framework for integrated genomic approaches in oncogene discovery.


Nature | 2008

CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

Ron Firestein; Adam J. Bass; So Young Kim; Ian F. Dunn; Serena J. Silver; Isil Guney; Ellen Freed; Azra H. Ligon; Natalie Vena; Shuji Ogino; Milan G. Chheda; Pablo Tamayo; Stephen Finn; Yashaswi Shrestha; Jesse S. Boehm; Supriya K Jain; Emeric Bojarski; Craig H. Mermel; Jordi Barretina; Jennifer A. Chan; José Baselga; Josep Tabernero; David E. Root; Charles S. Fuchs; Massimo Loda; Ramesh A. Shivdasani; Matthew Meyerson; William C. Hahn

Aberrant activation of the canonical WNT/β-catenin pathway occurs in almost all colorectal cancers and contributes to their growth, invasion and survival. Although dysregulated β-catenin activity drives colon tumorigenesis, further genetic perturbations are required to elaborate full malignant transformation. To identify genes that both modulate β-catenin activity and are essential for colon cancer cell proliferation, we conducted two loss-of-function screens in human colon cancer cells and compared genes identified in these screens with an analysis of copy number alterations in colon cancer specimens. One of these genes, CDK8, which encodes a member of the mediator complex, is located at 13q12.13, a region of recurrent copy number gain in a substantial fraction of colon cancers. Here we show that the suppression of CDK8 expression inhibits proliferation in colon cancer cells characterized by high levels of CDK8 and β-catenin hyperactivity. CDK8 kinase activity was necessary for β-catenin-driven transformation and for expression of several β-catenin transcriptional targets. Together these observations suggest that therapeutic interventions targeting CDK8 may confer a clinical benefit in β-catenin-driven malignancies.


Cancer Cell | 2009

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer

Krishna Vasudevan; David A. Barbie; Michael A. Davies; Rosalia Rabinovsky; Chontelle McNear; Jessica Kim; Bryan T. Hennessy; Hsiuyi Tseng; Panisa Pochanard; So Young Kim; Ian F. Dunn; Anna C. Schinzel; Peter Sandy; Qing Sheng; Piyush B. Gupta; Jesse S. Boehm; Jan H. Reiling; Serena J. Silver; Yiling Lu; Katherine Stemke-Hale; Bhaskar Dutta; Corwin Joy; Aysegul A. Sahin; Ana M. Gonzalez-Angulo; Ana Lluch; Lucia E. Rameh; Tyler Jacks; David E. Root; Eric S. Lander; Gordon B. Mills

Dysregulation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway occurs frequently in human cancer. PTEN tumor suppressor or PIK3CA oncogene mutations both direct PI3K-dependent tumorigenesis largely through activation of the AKT/PKB kinase. However, here we show through phosphoprotein profiling and functional genomic studies that many PIK3CA mutant cancer cell lines and human breast tumors exhibit only minimal AKT activation and a diminished reliance on AKT for anchorage-independent growth. Instead, these cells retain robust PDK1 activation and membrane localization and exhibit dependency on the PDK1 substrate SGK3. SGK3 undergoes PI3K- and PDK1-dependent activation in PIK3CA mutant cancer cells. Thus, PI3K may promote cancer through both AKT-dependent and AKT-independent mechanisms. Knowledge of differential PI3K/PDK1 signaling could inform rational therapeutics in cancers harboring PIK3CA mutations.


Molecular and Cellular Biology | 2000

A lipopolysaccharide-specific enhancer complex involving Ets, Elk-1, Sp1, and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo.

Eunice Y. Tsai; James V. Falvo; Alla V. Tsytsykova; Amy K. Barczak; Andreas M. Reimold; Laurie H. Glimcher; Matthew J. Fenton; David C. Gordon; Ian F. Dunn; Anne E. Goldfeld

ABSTRACT The tumor necrosis factor alpha (TNF-α) gene is rapidly activated by lipopolysaccharide (LPS). Here, we show that extracellular signal-regulated kinase (ERK) kinase activity but not calcineurin phosphatase activity is required for LPS-stimulated TNF-α gene expression. In LPS-stimulated macrophages, the ERK substrates Ets and Elk-1 bind to the TNF-α promoter in vivo. Strikingly, Ets and Elk-1 bind to two TNF-α nuclear factor of activated T cells (NFAT)-binding sites, which are required for calcineurin and NFAT-dependent TNF-α gene expression in lymphocytes. The transcription factors ATF-2, c-jun, Egr-1, and Sp1 are also inducibly recruited to the TNF-α promoter in vivo, and the binding sites for each of these activators are required for LPS-stimulated TNF-α gene expression. Furthermore, assembly of the LPS-stimulated TNF-α enhancer complex is dependent upon the coactivator proteins CREB binding protein and p300. The finding that a distinct set of transcription factors associates with a fixed set of binding sites on the TNF-α promoter in response to LPS stimulation lends new insights into the mechanisms by which complex patterns of gene regulation are achieved.


Nature Genetics | 2013

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations

Priscilla K. Brastianos; Peleg Horowitz; Sandro Santagata; Robert T. Jones; Aaron McKenna; Gad Getz; Keith L. Ligon; Emanuele Palescandolo; Paul Van Hummelen; Matthew Ducar; Alina Raza; Ashwini Sunkavalli; Laura E. MacConaill; Anat Stemmer-Rachamimov; David N. Louis; William C. Hahn; Ian F. Dunn; Rameen Beroukhim

Meningiomas are the most common primary nervous system tumor. The tumor suppressor NF2 is disrupted in approximately half of all meningiomas, but the complete spectrum of genetic changes remains undefined. We performed whole-genome or whole-exome sequencing on 17 meningiomas and focused sequencing on an additional 48 tumors to identify and validate somatic genetic alterations. Most meningiomas had simple genomes, with fewer mutations, rearrangements and copy-number alterations than reported in other tumors in adults. However, several meningiomas harbored more complex patterns of copy-number changes and rearrangements, including one tumor with chromothripsis. We confirmed focal NF2 inactivation in 43% of tumors and found alterations in epigenetic modifiers in an additional 8% of tumors. A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways. These mutations were present in therapeutically challenging tumors of the skull base and higher grade. These results begin to define the spectrum of genetic alterations in meningiomas and identify potential therapeutic targets.


Cancer Discovery | 2015

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

Priscilla K. Brastianos; Scott L. Carter; Sandro Santagata; Daniel P. Cahill; Amaro Taylor-Weiner; Robert T. Jones; Eliezer M. Van Allen; Michael S. Lawrence; Peleg Horowitz; Kristian Cibulskis; Keith L. Ligon; Josep Tabernero; Joan Seoane; Elena Martinez-Saez; William T. Curry; Ian F. Dunn; Sun Ha Paek; Sung-Hye Park; Aaron McKenna; Aaron Chevalier; Mara Rosenberg; Fred G. Barker; Corey M. Gill; Paul Van Hummelen; Aaron R. Thorner; Bruce E. Johnson; Mai P. Hoang; Toni K. Choueiri; Sabina Signoretti; Carrie Sougnez

UNLABELLED Brain metastases are associated with a dismal prognosis. Whether brain metastases harbor distinct genetic alterations beyond those observed in primary tumors is unknown. We performed whole-exome sequencing of 86 matched brain metastases, primary tumors, and normal tissue. In all clonally related cancer samples, we observed branched evolution, where all metastatic and primary sites shared a common ancestor yet continued to evolve independently. In 53% of cases, we found potentially clinically informative alterations in the brain metastases not detected in the matched primary-tumor sample. In contrast, spatially and temporally separated brain metastasis sites were genetically homogenous. Distal extracranial and regional lymph node metastases were highly divergent from brain metastases. We detected alterations associated with sensitivity to PI3K/AKT/mTOR, CDK, and HER2/EGFR inhibitors in the brain metastases. Genomic analysis of brain metastases provides an opportunity to identify potentially clinically informative alterations not detected in clinically sampled primary tumors, regional lymph nodes, or extracranial metastases. SIGNIFICANCE Decisions for individualized therapies in patients with brain metastasis are often made from primary-tumor biopsies. We demonstrate that clinically actionable alterations present in brain metastases are frequently not detected in primary biopsies, suggesting that sequencing of primary biopsies alone may miss a substantial number of opportunities for targeted therapy.


Journal of Neuro-oncology | 2000

Growth Factors in Glioma Angiogenesis: FGFs, PDGF, EGF, and TGFs

Ian F. Dunn; Oliver Heese; Peter McL. Black

It has become well accepted that solid tumors must create a vascular system for nutrient delivery and waste removal in order to grow appreciably. This process, angiogenesis, is critical to the progression of gliomas, with vascular changes accompanying the advancement of these tumors. The cascade of events in this process of blood vessel formation involves a complex interplay between tumor cells, endothelial cells, and their surrounding basement membranes in which enzymatic degradation of surrounding ground substance and subsequent endothelial cell migration, proliferation, and tube formation occurs. It is likely that a host of growth factors is responsible for mediating these key events. To date, a role for Vascular Endothelial Growth Factor (VEGF) in glioma angiogenesis has been convincingly demonstrated. This review explores the contribution of other growth factors–-Fibroblast Growth Factors (FGFs), Platelet-Derived Growth Factor (PDGF), Epidermal Growth Factor (EGF), and Transforming Growth Factors (TGFs)–-to glioma angiogenesis. These growth factors may influence glioma angiogenesis by directly stimulating endothelial cell proliferation, by mediating the expression of key proteases on endothelial cells necessary for angiogenesis, or by regulating the expression of VEGF and of each other.


Nature Genetics | 2014

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas

Priscilla K. Brastianos; Amaro Taylor-Weiner; Peter Manley; Robert T. Jones; Dora Dias-Santagata; Aaron R. Thorner; Michael S. Lawrence; Fausto J. Rodriguez; Lindsay A. Bernardo; Laura Schubert; Ashwini Sunkavalli; Nick Shillingford; Monica L. Calicchio; Hart G.W. Lidov; Hala Taha; Maria Martinez-Lage; Mariarita Santi; Phillip B. Storm; John Y. K. Lee; James N. Palmer; Nithin D. Adappa; R. Michael Scott; Ian F. Dunn; Edward R. Laws; Chip Stewart; Keith L. Ligon; Mai P. Hoang; Paul Van Hummelen; William C. Hahn; David N. Louis

Craniopharyngiomas are epithelial tumors that typically arise in the suprasellar region of the brain. Patients experience substantial clinical sequelae from both extension of the tumors and therapeutic interventions that damage the optic chiasm, the pituitary stalk and the hypothalamic area. Using whole-exome sequencing, we identified mutations in CTNNB1 (β-catenin) in nearly all adamantinomatous craniopharyngiomas examined (11/12, 92%) and recurrent mutations in BRAF (resulting in p.Val600Glu) in all papillary craniopharyngiomas (3/3, 100%). Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors). The CTNNB1 and BRAF mutations were clonal in each tumor subtype, and we detected no other recurrent mutations or genomic aberrations in either subtype. Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually exclusive and clonal. These findings have important implications for the diagnosis and treatment of these neoplasms.


Immunity | 2001

TRAF1 Is a Negative Regulator of TNF Signaling: Enhanced TNF Signaling in TRAF1-Deficient Mice

Erdyni Tsitsikov; Dhafer Laouini; Ian F. Dunn; Tatyana Sannikova; Laurie Davidson; Frederick W. Alt; Raif S. Geha

TNF receptor-associated factor 1 (TRAF1) is a unique TRAF protein because it lacks a RING finger domain and is predominantly expressed in activated lymphocytes. To elucidate the function of TRAF1, we generated TRAF1-deficient mice. TRAF1(-/-) mice are viable and have normal lymphocyte development. TRAF1(-/-) T cells exhibit stronger than wild-type (WT) T cell proliferation to anti-CD3 mAb, which persisted in the presence of IL-2 or anti-CD28 antibodies. Activated TRAF1(-/-) T cells, but not TRAF1(+/+) T cells, responded to TNF by proliferation and activation of the NF-kappa B and AP-1 signaling pathways. This TNF effect was mediated by TNFR2 (p75) but not by TNFR1 (p55). Furthermore, skin from TRAF1(-/-) mice was hypersensitive to TNF-induced necrosis. These findings suggest that TRAF1 is a negative regulator of TNF signaling.

Collaboration


Dive into the Ian F. Dunn's collaboration.

Top Co-Authors

Avatar

Wenya Linda Bi

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Sandro Santagata

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Ossama Al-Mefty

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Edward R. Laws

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brian M. Alexander

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Malak Abedalthagafi

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Alexandra J. Golby

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge